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Abstract 
Older adults who ultimately develop dementia experience accelerated cognitive decline long 
before diagnosis. A similar acceleration in cognitive decline occurs in the years before death as 
well. To evaluate preclinical and terminal cognitive decline, past researchers have incorporated 
change points in their analyses of longitudinal data, identifying point estimates of how many 
years prior to diagnosis or death that decline begins to accelerate. The current systematic review 
aimed to summarize the published literature on preclinical and terminal change points in relation 
to mild cognitive impairment (MCI), dementia, and death, identifying the order in which 
cognitive and neurological outcomes decline and factors that modify the onset and rate of 
decline. A systematic search protocol yielded 30 studies, describing 15 longitudinal cohorts 
modeling change points for cognitive and neurological outcomes preceding MCI, dementia, or 
death. Change points for cognitive abilities ranged from 3-4 years prior to MCI diagnosis, 1-11 
years prior to dementia diagnosis, and 3-15 years before death. No sequence of decline was 
observed preceding MCI or death, but the following sequence was tentatively accepted for 
Alzheimer’s disease: verbal memory, visuospatial ability, executive functions and fluency, and 
lastly verbal IQ. Some of the modifiers of the onset and rate of decline examined by previous 
researchers included gender, education, genetics, neuropathology, and personality. Change point 
analyses evidence accelerated decline preceding MCI, dementia, and death, but moderators of 
the onset and rate of decline remain ambiguous due to between-study modeling differences, and 
coordinated analyses may improve comparability across future studies. 
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CHANGE POINT SYSTEMATIC REVIEW  2 
When does cognitive decline begin? A systematic review of change point studies on 
accelerated decline in cognitive and neurological outcomes preceding mild cognitive 
impairment, dementia, and death 
An estimated 5.5 million Americans are currently living with Alzheimer’s disease (AD); 
and with the aging baby boomer generation and longer life expectancies, it is anticipated that this 
number will exceed 13 million by the year 2050 (Alzheimer's Association, 2017). Additionally, 
many individuals who experience subjective cognitive decline or Mild Cognitive Impairment 
(MCI) present with AD biomarkers (e.g., neurodegeneration, Meiberth et al., 2015, Spulber et 
al., 2012; amyloid burden, Amariglio et al., 2012) and some will go on to develop AD or another 
type of dementia (Mitchell & Shiri-Feshki, 2009). Individuals who ultimately receive a diagnosis 
of MCI or dementia typically have observable neurological and cognitive differences many years 
prior to diagnosis (Bäckman, Jones, Berger, Laukka, & Small, 2005; Ewers, Sperling, Klunk, 
Weiner, & Hampel, 2011). An appreciation for these preclinical differences has enhanced 
research focus on the early detection of cognitive change over the course of aging. 
Previous cross-sectional research has identified varying effects of preclinical AD on 
different domains of cognitive functioning (Bäckman et al., 2005). Although cross-sectional 
approaches offer insight into between-group differences, individual differences in within-person 
change can only be evaluated through longitudinal data and analysis. A longitudinal evaluation 
of the preclinical period has offered insight into when older adults undergo a change point over 
the course of cognitive aging, indicating an acceleration in the rate of cognitive decline 
preceding diagnosis (i.e., MCI or dementia) or death (i.e., terminal decline/drop; Palmore & 
Cleveland, 1976; Siegler, 1975). These change points often appear years before diagnosis or 
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death, providing insight into the sensitivity of different indicators exhibiting the earliest onset of 
accelerated decline.  
Change point studies are not unique to cognitive aging research (e.g., HIV; Ghosh & 
Vaida, 2007), but they have become increasingly popular within the field of aging since first 
applied to detect the onset of accelerated change in years prior to dementia (Hall, Lipton, 
Sliwinski, & Stewart, 2000; Joseph et al., 1999). The published literature on preclinical and 
terminal decline change points has grown extensively, analyzing data of multiple international 
cohorts from Australia (Batterham, Mackinnon, & Christensen, 2011), Canada (MacDonald, 
Hultsch, & Dixon, 2011), France (Jacqmin‐ Gadda, Commenges, & Dartigues, 2006), Sweden 
(Laukka, MacDonald, Fratiglioni, & Backman, 2012), the United Kingdom (Muniz-Terrera, van 
den Hout, Piccinin, Matthews, & Hofer, 2013; Muniz Terrera, Minett, Brayne, & Matthews, 
2014), and the United States (Grober et al., 2008; Wilson, Beckett, Bienias, Evans, & Bennett, 
2003; Wilson, Beck, Bienias, & Bennett, 2007). The international focus on change points aligns 
with the global scientific goal to identify the earliest possible biomarkers of neurodegenerative 
processes and modifiable risk factors associated with the onset or rate of cognitive decline 
(Alzheimer's Association, 2017). In turn, change point studies have focused not just on the 
acceleration of cognitive decline, but also the acceleration of neurological changes (Carlson, 
2008; Silbert et al., 2012) and variables that may delay or slow preclinical or terminal decline 
(e.g., education, cognitive activity; Hall et al., 2007; Hall et al., 2009; Muniz Terrera et al., 
2014).  
Despite the coherent mission of researchers to identify biomarkers and modifiable risk 
factors, change point studies vary considerably with respect to design, statistical model, inclusion 
of covariates, and the outcomes used as dependent variables. As such, there is a lack of 
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consensus regarding the order in which different neurological and cognitive domains decline and 
the factors that are associated with the onset and rate of decline in later age. Anticipating that 
researchers will continue to conduct change point analyses on longitudinal datasets of older 
adults, the current literature must be reviewed to determine common and disparate findings 
across studies, informing future researchers about appropriate analytical practices, which 
covariates to include in their models, and evidence for differential sensitivity of particular 
cognitive and neurological measures to detect within-person change and change points. In turn, 
the current systematic review aimed to summarize the published literature on change point 
models indicating the onset of accelerated decline in relation to MCI, dementia, and death, 
identifying (a) the order in which cognitive and neurological outcomes accelerate in their rate of 
decline preceding each clinical endpoint and (b) factors that modify the onset or rate of decline. 
Method 
The report for this systematic review was prepared following the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement (Moher, Liberati, 
Tetzlaff, Altman, & Grp, 2009).  
Literature search. The key words, subject headings and index terms used in the 
electronic search protocol included terms associated with MCI and dementia, terminal decline, 
cognitive and neurological outcomes, longitudinal methods, and change point analyses. The full 
list of search terms is provided in the supplementary materials. The electronic search involved 
four databases (i.e., CINHAHL Complete, MedLine with Full Text, PSYCInfo, and 
PSYCArticles) and was conducted in March 2017, with no filters placed on the search findings. 
Two reviewers independently reviewed the electronic search results to ensure no eligible studies 
were missed (Edwards et al., 2002). A manual search was also conducted, inclusive of reference 
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lists, targeted journals not indexed in psychological and biomedical databases (i.e., Journal of 
Applied Statistics, Computational Statistics and Data Analysis), and articles known by the 
authors but not detected by the electronic search strategy. 
Eligibility criteria. For inclusion in the systematic review, authors needed to (a) report a 
longitudinal study involving four or more measurement waves and (b) test a change point model 
for (c) either a cognitive or neurological outcome. The researchers needed to (d) test a model 
with a pre-clinical or terminal decline change point, modeled in relation to MCI onset, dementia 
onset, or death (i.e., models using age or time-in-study as the time metric were ineligibile). 
Participants included in analyses (e) needed to be free of concurrent neurological disorders other 
than dementia that could contribute to cognitive decline (e.g., Parkinson’s disease, stroke). If a 
small subsample (n < 5% of the sample) of participants were diagnosed with a concurrent 
neurological condition at baseline or during the course of the study, this study was included in 
the systematic review; however, if a majority of the sample was diagnosed with a concurrent 
neurological condition at baseline (e.g., Parkinson’s disease; Aarsland, Muniz, & Matthews, 
2011; Johnson, Langford, Garnier-Villarreal, Morris, & Galvin, 2016), the study was deemed 
ineligible. Further, (f) studies reporting samples with the majority experiencing early-onset 
dementia (i.e., mean age at onset <65) were also deemed ineligible (Aguirre-Acevedo et al., 
2016). Eligible articles needed to (g) be published in an academic journal or book and (h) be 
written in the English language. 
Data extraction. Two reviewers separately examined articles identified through the 
literature review to determine their eligibility for inclusion in the research synthesis. For all 
eligible studies, two reviewers independently extracted information following a common data 
collection instrument. The extracted data included participant characteristics, study 
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characteristics, and quantitative results. The participant characteristics included the sample size 
of participants that were included in the change point analysis, the baseline demographics of the 
sample (i.e., mean age, gender composition, years of education, ethnicity, and the percent with 
an apoE ε4 allele, APOE ε4), and the operational definition of MCI or dementia used for the 
sample. Study characteristics included the study duration in years, maximum number of 
measurement waves completed by any participant included in the analysis, the mean number of 
measurement waves completed by all participants included in the analysis, the mean number of 
years follow-up for all participants included in the analysis, and the interval duration between 
measurement occasions. Model information was recorded, including whether the estimation 
approach was Bayesian or frequentist and what covariates were included in the analysis. The 
names of the cognitive and neurological outcomes included in change point analyses were also 
extracted along with the change points for each outcome in relation to diagnosis or death along 
with a 95% Confidence or Credible Interval. 
  Individual and across study bias. The risk of bias within individual studies was not 
easily operationalized, as the criteria typically used to assess individual study bias and study 
quality are often written for intervention studies involving randomized controlled trials 
(Sanderson, Tatt, & Higgins, 2007; Vandenbroucke et al., 2007). Although certain 
recommendations for quality reporting in observational longitudinal analyses have been 
previously proposed (Tooth, Ware, Bain, Purdie, & Dobson, 2005), no study quality instrument 
designed for longitudinal change point analyses exists. Although individual study bias was not 
quantified, certain study characteristics (e.g., mean number of measurement waves in 
combination with study duration and maximum number of measurement waves) gave a proxy for 
attrition bias, with these findings qualitatively interpreted in aggregate within the discussion. As 
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well, bias across studies was also not quantified, but certain types of across study bias (e.g., 
publication bias, selective reporting) was covered in the discussion as potentially affecting the 
interpretation of results. 
Results 
Literature Search 
 Figure 1 provides a flow diagram of the systematic review process. Among the 74 articles 
originally identified through electronic and manual search strategies, a total of 30 articles 
ultimately met eligibility criteria for inclusion in the systematic review. References for full text 
articles that were reviewed by the authors, but did not ultimately meet inclusion criteria are 
provided in the supplementary materials and sorted by their reason for exclusion. Among these 
30 articles, 4 evaluated change points in relation to MCI diagnosis, 12 evaluated change points in 
relation to dementia diagnosis, and 14 evaluated change points in relation to death. A total of 15 
different longitudinal cohorts were represented across the articles, including the Alzheimer’s 
Disease Centers Neuropsychological Database Initiative (Ji, Xiong, & Grundman, 2003), Bronx 
Aging Study (BAS; Hall et al., 2007; Hall et al., 2009; Hall et al., 2000; Hall, Ying, Kuo, & 
Lipton, 2003; Hall et al., 2001; Sliwinski et al., 2006), Baltimore Longitudinal Study of Aging 
(Grober et al., 2008), Cambridge City over 75 Cohort Study (CC75C; Muniz-Terrera et al., 2013; 
Muniz Terrera et al., 2014; van den Hout, Muniz‐ Terrera, & Matthews, 2011), Canberra 
Longitudinal Study (Batterham et al., 2011), Gerontological and Geriatric Population Study 
(H70; Thorvaldsson et al., 2008; Thorvaldsson et al., 2011), Kungsholmen Project (KP; Laukka 
et al., 2012; Thorvaldsson et al., 2011), Monongahela Valley Independent Elders Survey (Dodge, 
Wang, Chang, & Ganguli, 2011), Oregon Brain Aging Study (OBAS; Buracchio, Dodge, 
Howieson, Wasserman, & Kaye, 2010; Carlson, 2008; Howieson et al., 2008; Silbert et al., 
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2012), Origins of Variance in the Old-old Study (van den Hout, Muniz-Terrera, & Matthews, 
2013), Paquid Project (Jacqmin‐ Gadda et al., 2006), Religious Orders Study/Memory and 
Aging Project (ROS/MAP; Boyle et al., 2013; Li, Dowling, & Chappell, 2015; R. Wilson et al., 
2003; Wilson et al., 2007; Wilson et al., 2015; Yu et al., 2013), Victoria Longitudinal Study 
(MacDonald et al., 2011), and lastly a cohort from the Washington University School of 
Medicine Alzheimer’s Disease Research Center (Johnson, Storandt, Morris, & Galvin, 2009). 
 The following sections will discuss the findings of change point studies based on their 
clinical endpoint: MCI, dementia, or death. Each section will cover the demographic information 
of the samples evaluated, discuss study design characteristics, and summarize the findings of the 
change point analyses, including the effects of moderating variables that influenced either the 
location of the change point in relation to diagnosis or death or the rate of decline before or after 
the change point. For MCI, dementia, and terminal decline change point studies, respectively, 
Tables 1-3 summarize the demographic information for the participants included in each 
analysis, and Tables 4-6 summarize the design characteristics and reported change points. 
Preclinical MCI Change Point Studies 
Demographic characteristics. Four studies examined change points in relation to the 
diagnosis of MCI (Buracchio et al., 2010; Carlson, 2008; Howieson et al., 2008; Silbert et al., 
2012), all analyzing participant data from the OBAS. MCI was defined as having two or more 
consecutive scores of ≥0.5 on the Clinical Dementia Rating Scale (Morris, 1993) along with no 
functional impairment. The sample sizes with MCI ranged from 37 to 134 across studies, with a 
baseline age of about 84 years. This sample was predominantly female (~60-65%), White 
(~98%) and well-educated, with participants having about 13 to 14 years of education on 
average. Roughly 20-25% of participants were carriers of the APOE ε4 allele.  
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Design characteristics. The OBAS studies involved samples with up to 20 years of 
follow-up, with annual neurological and neuropsychological assessments. The average number 
of years follow-up ranged from 6.3 to 10.5 depending on the sample used for each study. The 
modeling approach to the OBAS data was entirely based on profile likelihood methods with 
fixed change points (Hall et al., 2000).  
Summary of findings. Figure 2 provides a forest plot of change points for the MCI 
studies, organized by the type of outcome evaluated (i.e., motor, neurological, and cognitive). On 
three measures of motor function (i.e., gait speed and finger tapping for each hand), men showed 
an earlier decline than women. The onset of decline in finger tapping occurred near or even after 
MCI diagnosis, while gait speed showed the earliest change point for any outcome: -6.0 years 
(95% CI: -9.5, -4.6) and -14.2 years (Unknown, -8.7) before diagnosis for men and women, 
respectively. In comparison to change point analyses in relation to dementia or terminal decline, 
only MCI studies explored preclinical change points for non-cognitive outcomes. As shown 
visually in Figure 2, motor and neurological change points were on average earlier than cognitive 
change points; however, the 95% CIs around change points for cognitive and neurological 
outcomes were far broader than those observed for cognitive outcomes. 
Preclinical Dementia Change Point Studies 
Demographic characteristics. Twelve studies examined change points in cognitive 
functioning in relation to dementia diagnosis. A total of nine cohorts were evaluated in these 
analyses, with two of these cohorts combined and evaluated as a single sample in one study (i.e., 
ROS/MAP; Li et al., 2015). Taking the largest sample size reported by a study for each cohort, a 
total of 1,662 participants that progressed to dementia during follow-up were represented in the 
systematic review. The mean baseline age of participants across studies ranged from 70 to 82 
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years. The only cohort with reported ethnicity data was the BAS and the sample was over 90% 
White (Hall et al., 2007; Hall et al., 2009). Two samples reported the percent prevalence of the 
APOE ε4 allele in their sample, with values of 27.0% and 29.6% (Johnson et al., 2009; Li et al., 
2015). The education of the samples varied substantially, from samples where most participants 
had some college education (Grober et al., 2008; Ji et al., 2003; Johnson et al., 2009) to samples 
where most participants had equal to or fewer than 12 years (Hall et al., 2007; Li et al., 2015), 
fewer than 8 years (Laukka et al., 2012), and fewer than 6 years (Thorvaldsson et al., 2011). The 
majority of participants from one sample did not complete primary school (Jacqmin‐ Gadda et 
al., 2006). 
In terms of dementia diagnosis, five cohorts used criteria from the Diagnostic and 
Statistical Manual for Mental Disorders, Third Edition (DSM-III; American Psychiatric 
Association, 1980) or Third Edition, Revised (DSM-III-R; American Psychiatric Association, 
1987). In terms of subtypes of dementia, four studies (Grober et al., 2008; Hall et al., 2000; 
Laukka et al., 2012; Li et al., 2015) cited specific criteria to define AD (McKhann et al., 2011), 
while two other studies (Hall et al., 2000; Laukka et al., 2012) cited criteria to define Vascular 
Dementia (Román et al., 1993) or Multi-Infarct Dementia (Rosen, Terry, Fuld, Katzman, & 
Peck, 1980). Two studies did not cite established criteria for diagnosing AD, but instead 
provided their own criteria (Johnson et al., 2009) or asserted the sample had an AD diagnosis 
without offering an operational definition (Ji et al., 2003). 
Design characteristics. The cohorts used to estimate preclinical dementia change points 
ranged in years of follow-up from 10 years to up to 30 years. The interval between measurement 
waves varied by cohort from annual assessments to assessments occurring every three years. The 
average years of follow-up or number of measurement waves completed was not consistently 
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reported across cohorts. In terms of analytical approach, most studies took a frequentist 
estimation approach with a fixed change point; however, two studies applied both Bayesian and 
frequentist approaches, calculating both fixed and random change points (Hall et al., 2003; Hall 
et al., 2001). One frequentist study calculated a random change point (Jacqmin‐ Gadda et al., 
2006) and another conducted a quantile regression with a change point (Li et al., 2015).  
Summary of findings. Among the dementia change point studies, a few different 
moderators were evaluated to determine their influence on components of the change point 
model (i.e., the change point and the slopes before and after the change point). These moderators 
included demographics (e.g., gender, education), frequency of engagement in cognitive 
activities, dementia subtype, genetic risk (i.e., presence of APOE ε4), and the cognitive construct 
evaluated. 
Demographics. One study evaluated the effects of both gender and education on model 
components (Li et al., 2015). These researchers reported no gender or education-related 
differences for the change point, and further reported no gender differences for the rate of change 
before or after the change point. The effect of education on slopes before and after the change 
point was not discussed. Although no other studies evaluated the relationship between gender 
and model components, two additional studies examined the effect of education. Among the 
BAS cohort, participants experienced a delay in their verbal memory change point, as measured 
by the Buschke Selective Reminding Test (BSRT), of roughly 2 months (i.e., 0.21 years) for 
each year of additional education; and while there were no significant education-related 
differences in the rate of decline prior to the change point, the rate of decline following the 
change point was faster for individuals with more years of education (Hall et al., 2007). 
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An additional study that explored the effects of education on preclinical change found a 
similar pattern of results (Jacqmin‐ Gadda et al., 2006). The change point was delayed for 
participants with more education, where individuals with at least a primary school diploma had a 
median onset of accelerated decline at 90.3 years (89.3, 91.4) and individuals with either no 
education or without a primary school diploma had a median onset of accelerated decline at 69.7 
years (65.0, 74.6). Following the change point, the rate of decline was more rapid for participants 
with a higher level of education, which meant that the median distance between the change point 
and dementia diagnosis was smaller for participants with more education (e.g., for a change point 
at 65 years, the age at dementia diagnosis was a median of 73.1 and 83.4 years for participants 
with high and low educational backgrounds, respectively). 
Frequency of cognitive activities. In the BAS, participants were queried at baseline for 
the frequency at which they engaged in cognitively engaging leisure activities (i.e., reading, 
writing, crossword puzzles, board/card games, group discussions, and playing music; Hall et al., 
2009). For each additional day of cognitive activity (i.e., participation in one cognitively 
engaging activity for one day in a week), the change point for the BSRT tasks was delayed by a 
little more than 2 months (i.e., 0.18 years), but following the change point, preclinical decline 
occurred more rapidly for participants engaged in more cognitive activities. This pattern was 
observed for participants progressing to dementia and was replicated for a sub-sample of 
participants progressing to AD specifically. When education was added to the model, fit did not 
improve and an interaction between education and cognitive activity was non-significant, 
although both remained uniquely predictive of a delayed change point and a more rapid rate of 
preclinical decline. 
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Dementia subtype. Two studies evaluated the KP dataset (Laukka et al., 2012; 
Thorvaldsson et al., 2011). The first evaluation identified change points for different cognitive 
constructs in relation to dementia diagnosis in general (Thorvaldsson et al., 2011), whereas the 
second study explored differences in the location of the change point in relation to diagnosis for 
two different dementia types: AD and VaD (Laukka et al., 2012). These authors found that for 
every cognitive test except for Clock Reading, the onset of preclinical decline occurred earlier 
for AD than VaD by approximately two to four years. When AD and VaD samples were 
combined, the change points for the Block Design and Word Recall tasks were -8.3 years 
(Unknown, -5.4) and -8.6 years (Unknown, -6.2), respectively (Thorvaldsson et al., 2011); 
however, the change points for these tests were different when the sample was sub-divided based 
on dementia subtype. The earliest change point observed for AD patients involved the Block 
Design task (i.e., -9.6 years [Unknown, -6.8]), and the earliest change point observed for VaD 
involved Word Recall (i.e., -6.5 years [Unknown, -3.1]). 
Genetic risk. Only one study evaluated the effect of genetic risk on the change point 
model parameters, using a quantile regression approach to determine the effect of moderators at 
different quantiles of performance on a composite measure of verbal memory (Li et al., 2015). 
The presence of an APOE ε4 allele did not affect the location of the change point in relation to 
AD diagnosis, but it did lower the intercept (i.e., level of verbal memory at age 65) for 
participants in the 20th and 50th percentiles. APOE ε4 allele carriers in the 20th percentile also had 
a slower rate of decline, which was likely a consequence of a lower starting point in comparison 
to individuals without genetic risk. 
Cognitive construct. In terms of dementia cohorts in general, the earliest observed 
change point was for a measure of processing speed (i.e., Figure Identification), occurring -10.9 
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years (-14.4, -7.5) before diagnosis (Thorvaldsson et al., 2011); however, the earliest change 
point for AD-only samples was observed for Block Design, a measure of visuospatial ability, 
with a change point of -9.6 years (Unknown, -6.8) (Laukka et al., 2012). The most commonly 
measured domain was verbal memory, with change points for dementia ranging from -1.0 years 
to -8.6 years (Unknown, -6.2) (Thorvaldsson et al., 2011) before diagnosis. The latest cognitive 
ability to decline was verbal IQ as measured by a test of reading ability. The change point was -
0.4 years (-1.1, 0.1) before diagnosis with a 95% CI inclusive of possible values after the 
diagnosis of AD (Grober et al., 2008). 
Figure 3 provides a forest plot of change points for AD-only sample coded in years to 
diagnosis with 95% CIs when reported by the authors. The change points were categorized in 
terms of the cognitive construct evaluated by the test used to calculate the change point, as 
determined by the authors of this review. The decision to only include AD samples in the forest 
plot was to ensure the change points were as comparable as possible across studies, assuming a 
common pathological pathway underlying the cognitive changes observed for each sample. As 
shown visually in Figure 3, substantial variability in change points were observed both within 
and between cognitive constructs. An exact sequence of decline based on cognitive construct 
could not be determined, considering the substantial scatter among change point estimates for the 
same cognitive constructs, the limited data points reported for some cognitive constructs, and the 
overlap between the CIs around different change points.  
Terminal Decline Change Point Studies 
Demographic characteristics. Fourteen studies examined change points in cognitive 
functioning prior to death. A total of nine cohorts were evaluated in these analyses, with two of 
these cohorts combined and evaluated as a single sample in three studies (i.e., ROS/MAP) 
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(Boyle et al., 2013; Wilson et al., 2015; Yu et al., 2013), but kept separate in two other studies 
(i.e., MAP-only (R. S. Wilson et al., 2007); ROS-only (Wilson et al., 2003). Taking the largest 
sample size reported by a study for each cohort, a total of 5,613 participants that passed away 
during follow-up were represented in the systematic review, with 37% of these participants 
coming from a single cohort (i.e., CC75C, n = 2,078; Muniz Terrera et al., 2014). The mean 
baseline age of participants across studies ranged from 72.7 to 88.9 years. The only cohorts with 
ethnicity data were the ROS-only (Wilson et al., 2007) and ROS/MAP combined cohorts (Boyle 
et al., 2013), reporting 91.6% and 95% White samples, respectively. The percent prevalence of 
the APOE ε4 allele was reported for two samples: the MAP-only (29.5%) (Wilson et al., 2007) 
and ROS/MAP combined cohorts (23.8%; Yu et al., 2013). The education of the samples ranged 
from means of 11.4 years (Batterham et al., 2011) to 18.3 years (Wilson et al., 2003). Two 
samples described the educational backgrounds of their samples categorically. One study 
described a sample where the majority had completed at least high school education (i.e., 54.3%; 
Dodge et al., 2011), while the other study reported that participants left formal education on 
average at 14.8 years of age (Muniz Terrera et al., 2014). 
Design characteristics. The cohorts used to determine change points for the onset of 
terminal decline ranged in years of follow-up from 8 years to up to 30 years. The intervals 
between measurement waves varied by cohort from annual assessments, to assessments 
occurring every three years, to irregular assessments occurring every two to five years. As with 
dementia studies, terminal decline studies inconsistently reported the average years of follow-up 
or number of measurement waves completed across cohorts. The mean number of measurement 
waves completed by participants ranged from 2 waves (Batterham et al., 2011; MacDonald et al., 
2011) to 8.6 waves (Boyle et al., 2013). The number of measurement waves completed differed 
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from the average number of years follow-up, which ranged from 5.7 years (Sliwinski et al., 
2006) to 10.7 years (Wilson et al., 2015). In terms of analytical approach, seven studies took a 
frequentist approach with a fixed change point, while one study also took a frequentist approach, 
but included a random change point (van den Hout et al., 2013). A total of six studies conducted 
a Bayesian analysis with a random change point. 
Summary of findings. In comparison to the dementia change point studies, far more 
moderators were evaluated in the terminal decline studies. These studies determined the 
influence of moderators on the change point (i.e., the onset of terminal decline) along with the 
slope before the change point (i.e., the rate of age-related cognitive decline) and the slope after 
the change point (i.e., the rate of terminal decline). These moderators included demographics 
(e.g., age, gender, education), physical impairment, cognitive impairment, genetic risk, 
neuropathology, personality, practice effects, and cognitive construct. 
Demographics. The demographics examined as potential moderators included age at 
baseline or death, gender, and educational background. One study identified that participants 
older at baseline declined at a slightly faster rate before the change point, but declined at a slower 
rate following the change point (Muniz-Terrera et al., 2013), while another study found no 
relationship between age and the rate of terminal decline (Wilson et al., 2007). Participants older 
at death declined at slower rates prior to the change point than those who died younger; however, 
after the change point, those who died later had more rapid change than those who died younger 
(Muniz-Terrera et al., 2013; Muniz Terrera et al., 2014). 
Gender was evaluated twice using the same cohort (i.e., CC75C), but was associated with 
different results across studies. One study found that women declined at the same rate as men 
before the change point, but at a faster rate than men after the change point (Muniz-Terrera et al., 
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2013); while another study found that women declined at a faster rate than men before the 
change point, but at a slower rate than men after the change point (Muniz Terrera et al., 2014). 
In terms of education, four studies evaluated the effect of education on change point 
models examining terminal decline on the MMSE (Batterham et al., 2011; Muniz-Terrera et al., 
2013; Muniz Terrera et al., 2014; Wilson et al., 2007). In an analysis of two groups stratified at 
11 years of education (i.e., <11 years or ≥11 years), the low education group had a later change 
point than the high education group on the MMSE: -2.6 years (-3.8, -2.1) and -8.6 years (-10.1, -
7.7), respectively (Batterham et al., 2011). However, the rates of preterminal and terminal 
decline on the MMSE were greater for the low education group when compared to the high 
education group (Batterham et al., 2011). Another study also using the MMSE as the outcome 
measure observed a different effect of education on the location of the change point. This study 
(Muniz Terrera et al., 2014) had education coded as the age at which participants left formal 
schooling. Leaving school at a later age delayed the change point by 4.8 months per additional 
year of education, and thus participants with more education had a later onset of slightly faster 
decline. And yet another study examining the MMSE found a different pattern, where 
participants with more education experienced a faster decline on the MMSE prior to the change 
point in comparison to individuals with less education; however, following the onset of terminal 
decline, this pattern was reversed, where more educated participants declined at a slower rate 
than those participants with less education (Muniz-Terrera et al., 2013). Although not examining 
the MMSE, a different study (Wilson et al., 2007) found that the rate of terminal decline on a 
global composite measure of cognitive function did not vary by education.  
Only one study examined the effect of education on change point models of specific 
cognitive constructs (Batterham et al., 2011). As noted earlier, these authors provided point 
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estimates of change points for low and high education groups (i.e., <11 years or ≥11 years, 
respectively). Because the confidence intervals for the change point estimates overlapped, the 
authors suggested that education did not modify the onset of terminal decline in processing speed 
or episodic memory tests. Interestingly, the Episodic Memory score had very similar change 
points for the low education (i.e., -5.5 years [-8.3, -2.8]) and high education (i.e., -6.6 years [-6.9, 
-5.5]) groups; however, the point estimates for the Symbol-Letters Modalities Test (SLMT), a 
measure of processing speed, were further apart for low and high education groups: -11.3 years 
(<-17, -4.8) and -7.8 (-9.3, -6.8). For both the MMSE and Episodic Memory score, the low 
education group had a later change point than the high education group; however, for the 
processing speed task, participants with less education showed an earlier change point estimate. 
There was no difference based on education in preterminal decline for the SLMT, but the high 
education group showed faster terminal decline for this construct (i.e., potentially later onset, but 
faster decline). In an opposite pattern, there were no education-based differences in terminal 
decline for Episodic Memory scores; however, the high education group showed faster 
preterminal decline than the low education group for this outcome. 
Physical impairment and health problems. The effects of physical impairment on rates 
of cognitive decline did not reach significance either before or after the change point (Muniz-
Terrera et al., 2013; Muniz Terrera et al., 2014). Another study (Wilson et al., 2003) did not 
report significant changes in their model upon controlling for baseline medical conditions and 
physical disability. A different study that explored physical health as a moderator found no 
association between vascular risk factors (i.e., diabetes, smoking and hypertension) and terminal 
decline, but did find that the presence of vascular conditions (i.e., heart attack, stroke, 
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claudication, congestive heart failure) was related to terminal decline, in that terminal decline 
was absent when an individual had a vascular condition (Wilson et al., 2007). 
Cognitive impairment. The effect of cognitive impairment on components of the change 
point models varied across studies. One study found that participants with baseline cognitive 
impairment declined more rapidly both before and after the change point (Muniz Terrera et al., 
2014), while another study found that participants with baseline cognitive impairment declined at 
a slower rate before the change point and a faster rate after the change point (Muniz-Terrera et 
al., 2013). Yet another study found no association between the presence of mild cognitive 
impairment and the rate of terminal decline (Wilson et al., 2007). Two studies specifically 
evaluated the effects of participants with dementia on components of their change point models. 
For one study, participants with dementia had a lower baseline performance, but did not differ 
from participants without dementia in their rate of cognitive decline before the change point; 
however, they experienced a faster rate of decline following the change point (Sliwinski et al., 
2006). In contrast, for another cohort, the exclusion of participants with a dementia diagnosis did 
not substantially affect the location of the change point or the rates of preterminal or terminal 
decline (Batterham et al., 2011). 
Genetic risk. Two studies examined the relationship between the presence of the APOE 
ε4 allele and components of their change points models, one examining the combined ROS/MAP 
cohorts (Yu et al., 2013) and another examining just the MAP cohort (Wilson et al., 2007). When 
evaluating the associations between APOE ε4 status and the components of the change point 
model, one study identified an earlier change point for APOE ε4 carriers by roughly 9 months 
(Yu et al., 2013). In terms of rates of cognitive decline before and after the change point, APOE 
ε4 carriers had a 75% faster rate of preterminal decline and a 40% faster rate of terminal decline 
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compared to non-carriers. In contrast, a different study found that the presence of an APOE ε4 
allele was associated with a more rapid terminal decline, but was unassociated with the rate of 
preterminal decline (Wilson et al., 2007). The study examining the combined cohorts also 
explored the potential protective effects of possessing an APOE ε2 allele, but found no evidence 
that the presence of the ε2 allele was associated with any component of the change point model 
(Yu et al., 2013). 
Neuropathology. A set of studies analyzing the ROS/MAP combined cohorts examined 
the effects of different indicators of neuropathology and genetic risk on the components of their 
change point models for a global cognition composite score (Boyle et al., 2013; Wilson et al., 
2015; Yu et al., 2013). One of these studies further examined the relationship between 
conscientiousness and neuropathology (Wilson et al., 2015), with the findings of these 
researchers explained under the personality subsection below. The indices of neuropathology 
evaluated included neurofibrillary tangle density (hereafter referred to as tangles) and amyloid 
plaque burden (hereafter referred to as amyloid), along with the presence of micro-infarcts, gross 
infarcts, neocortical Lewy bodies or hippocampal sclerosis. Global AD pathology was also 
derived as an average of the summary scores given for tangles, neuritic plaques, and diffuse 
plaques. 
In a study that included all neuropathologic indices in the same model, these indices 
accounted for 25% of variation in the change point, 32% of variation in the rate of change before 
the change point, and 21% of variation in the rate of change after the change point (Boyle et al., 
2013). The location of the change point was associated with global AD pathology, tangles, and 
the presence of gross infarcts, micro-infarcts and neocortical Lewy bodies; the rate preterminal 
decline was associated with global AD pathology, tangle density, and the presence of gross 
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infarcts and Lewy bodies; and lastly, the rate of terminal decline was associated with tangles and 
the presence Lewy bodies. Notably, amyloid was not associated with any component of the 
change point model, potentially due to the inclusion of Global AD pathology as a covariate (i.e., 
these two variables correlated at r = 0.78). In another study (Wilson et al., 2015), tangles and the 
presence of Lewy bodies, gross infarcts and hippocampal sclerosis were included as covariates in 
a change point model, identifying associations between the preterminal slope and three 
neuropathologic indices (i.e., tangles, Lewy bodies and hippocampal sclerosis, accounting for 
25.9% of variation) and the terminal slope and two neuropathologic indices (i.e., Lewy bodies 
and gross infarcts, accounting for 13.2% of variation). 
Another group of researchers (Yu et al., 2013) examined the same neuropathologic 
indices, but evaluated their association with components of the change point model after 
accounting for variance attributable to the presence of an APOE ε4 allele. The relationship 
between APOE ε4 status and components of the change point model were discussed above in the 
genetic risk subsection. When included in the model, AD pathology was associated with an 
earlier change point and faster rates of decline before and after the change point. The 
associations between APOE ε4 status and all components of the change point model were all 
attenuated by the inclusion of AD pathology and became non-significant, albeit the association 
between the rate of terminal decline and APOE ε4 status remained marginally significant. When 
examining tangles and amyloid separately, both were associated with an earlier change point and 
more rapid rates of preterminal and terminal decline, although the association between amyloid 
and terminal decline was only a trend. When controlling for amyloid burden, the presence of an 
APOE ε4 allele was still significantly associated with all three components of the change point 
model. When controlling for tangles, the presence of an APOE ε4 allele was no longer 
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significantly associated with the rate of preterminal decline or the location of the change point, 
but maintained a modest association with the rate of terminal decline. When controlling for both 
amyloid and tangles simultaneously, APOE ε4 was not associated with any component of the 
model, amyloid was only associated with an earlier change point, and tangle density was still 
associated with all components of the change point model. 
Gross infarcts were not associated with the location of the change point, but were 
associated with faster rates of preterminal and terminal decline. In contrast, microscopic infarcts 
were associated with an earlier change point, but not the rates of decline (Yu et al., 2013). The 
relationships between APOE ε4 status and components of the change point model were 
unaffected when controlling for the presence of infarcts. A final model run by these authors 
accounted for global AD pathology, infarcts, Lewy bodies and APOE ε4 status simultaneously. 
This model found that AD pathology and microscopic infarcts were associated with an earlier 
change point, while AD pathology, macroscopic infarcts and Lewy bodies were associated with 
faster rates of cognitive decline before and after the change point. Upon accounting for all 
neuropathologic indices, the presence of an APOE ε4 allele was not associated with any 
component of the change point model. 
Personality. One study (Wilson et al., 2015) involved a series of models evaluating the 
relationship between personality and cognitive decline. The first model evaluated just the 
relationship between conscientiousness and the components of the change point model, finding 
that conscientiousness was not associated with the location of the change point. Higher 
conscientiousness was associated with a slower rate cognitive decline following the change 
point, but not before the change point. This relationship (i.e., higher traits leading to slower 
terminal decline) was true for all facets of conscientiousness (i.e., orderliness, goal striving, and 
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dependability) and all domains of cognition evaluated (i.e., global, episodic, semantic, and 
working memory), except for perceptual speed and visuospatial ability. In contrast to 
conscientiousness, neuroticism, baseline depressive symptoms, and the personality facets of 
negative affect and self-reproach were not associated with any component of the change point 
model. When included in a model with neuropathologic indices (i.e., tangles and the presence of 
Lewy bodies, gross infarcts or hippocampal sclerosis), conscientiousness was still associated 
with a slower rate of decline following the change point, accounting for 4.0% of additional 
variance in the terminal slope. When an interaction between conscientiousness and various 
neuropathologic indices were included in the model, an association was observed between 
conscientiousness, Lewy bodies and the terminal slope, where the relationship between Lewy 
bodies and the terminal slope was attenuated at higher levels of conscientiousness. In a closer 
examination of the stages of Lewy body disease (i.e., nigral, limbic, and neocortical), the 
researchers observed that conscientiousness specifically modified the association between 
terminal slope and neocortical Lewy body disease. 
Practice effects. A single group of researchers (Dodge et al., 2011) ran change points 
models with and without adjusting for practice effects (i.e., using dummy variables for the 
number of assessments), and identified that change points shifted further from death for three 
constructs (i.e., learning, memory, language) when practice effects were considered in the model. 
There was no shift in the change point for executive functions after controlling for practice 
effects, and a slight shift for the psychomotor speed change point (i.e., ~1 year earlier). 
Cognitive construct. Figure 4 provides a forest plot of change points preceding terminal 
decline coded in years to diagnosis with 95% CIs presented when reported by the authors. The 
change points are organized in terms of the cognitive construct evaluated, as categorized by the 
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authors of this review, and substantial variability in change points was observed both within and 
between most cognitive constructs. The most commonly measured domain was memory and 
learning, which includes tasks measuring learning and verbal or visual memory. Change points 
for this domain ranged from -3.4 years (Wilson et al., 2003) to -8.4 years (-9.8, -7.1) (Sliwinski 
et al., 2006) before diagnosis. When excluding the earliest change point, which was a slight 
outlier based on visual examination of Figure 4, the change points within this domain were fairly 
comparable, with the lower bound for this range moving to -6.6 years before death (Batterham et 
al., 2011). 
As with dementia cohorts, the earliest observed change point was for a measure of 
processing speed (i.e., Figure Identification) among the H70 cohort, with the change point 
preceding death by -14.8 years (-16.6, -10.8; Thorvaldsson et al., 2008). In terms of the latest 
cognitive ability to decline, change points for various domains using the ROS dataset were very 
similar for global cognition, processing speed, memory and learning, executive function, and 
language (range: -2.8 to -3.8; Wilson et al., 2003). The ROS cohort experienced a later onset of 
decline across most cognitive domains in comparison to other cohorts, as displayed visually in 
Figure 4. Interestingly, as a cognitive domain, processing speed had both the earliest and latest 
change points observed across samples, with processing speed presenting with the latest change 
point for the ROS cohort. Unlike for the dementia cohorts, verbal IQ, as measured by a test of 
vocabulary and semantic knowledge, did not have the latest change point. Instead, this construct 
began declining around -6.4 to -8.2 years before death (MacDonald et al., 2011), which was 
comparable to change point estimates for other domains. 
Not displayed visually in Figure 4, one study could not reliably estimate change points on 
tests of word reading (i.e., the National Adult Reading Test), verbal fluency, face recognition, 
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and word recognition (Batterham et al., 2011). For many constructs, there were few change 
points estimates reported in the literature overall (e.g., visuospatial ability, executive function, 
language). As with the dementia cohorts, an exact sequence of decline for cognitive constructs 
could not be determined based on the current findings, considering variability within cognitive 
constructs, limited data points for some cognitive constructs, and the overlap between the 
confidence/credible intervals around different change points. 
Discussion 
Since the first application of change point modeling in dementia populations (Joseph et 
al., 1999), the research within this area has steadily progressed, with 30 eligible studies evaluated 
in the current review. Among these studies, change points were examined in relation to MCI, 
dementia, and death, with researchers modeling numerous motor, neurological, and cognitive 
outcomes. The primary aims of this systematic review included identifying the order in which 
different neurological and cognitive outcomes decline in relation to diagnosis or death, and the 
determination of factors that modify the rate of decline or the location of the change point for 
each of these outcomes. In terms of the first aim, as detailed through the summary of results, the 
findings do not provide a clear and definitive temporal sequence by which different domains 
decline in the years preceding MCI or death, but offered some indication of a sequence preceding 
AD. 
Temporal Sequence of Cognitive Decline 
Only studies examining MCI explored change points in neurological outcomes, and 
although these researchers identified early change points for gait speed and white matter 
hyperintensities, this examination of pre-MCI change points has involved only one cohort (i.e., 
OBAS) with very small sample sizes (i.e., N range: 37 to 134) and an unidentified lower bound 
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of the CI surrounding their change points (Buracchio et al., 2010; Carlson, 2008; Howieson et 
al., 2008; Silbert et al., 2012). If you only consider the pre-MCI change points with estimates for 
both upper and lower bounds of their CIs, all outcomes (i.e., both cognitive and neurological) 
occur within the five years preceding diagnosis, apart from finger tapping, which occurs after 
diagnosis (see Figure 2). 
In regards to dementia, there was more evidence to suggest a sequence of decline 
preceding AD. A visual examination of Figure 3 appears to indicate an early decline in verbal 
memory, followed by visuospatial ability, then fluency and executive functions, and lastly verbal 
IQ. This interpretation is debatable, as this trend was not quantitatively determined, but rather 
based on a qualitative interpretation of the change points reported across studies. Many of the 
observed change points have either no reported CI or a very wide CI, overlapping with the 
intervals for other constructs. Further, some of the estimates for these domains (e.g., verbal IQ, 
executive functions) derive from just one to two studies (Grober et al., 2008; Johnson et al., 
2009), and have consequently not been critically evaluated through either direct of conceptual 
replications. In turn, while there is some evidence for a trend, this conclusion is a tentative one at 
best. Nonetheless, it does align with previous reviews of cross-sectional research evaluating 
cognitive deficits associated with preclinical AD (Bäckman et al., 2005; Duke Han, Nguyen, 
Stricker, & Nation, 2017). One construct sensitive to preclinical AD based on these review (i.e., 
processing speed) was only evaluated in the context of general dementia, rather than specifically 
AD (Thorvaldsson et al., 2011), but it was the earliest observed change point across studies. 
Future researchers should consider including processing speed outcomes in future change point 
analyses of preclinical AD, considering its relationship to white matter integrity (Gunning-Dixon 
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& Raz, 2000) and the early increase of white matter intensities preceding MCI (Silbert et al., 
2012). 
In contrast to pre-dementia change points, terminal change point studies did not provide 
evidence of a temporal sequence in cognitive decline preceding death. With the exception of one 
study finding change points across cognitive domains within five years of death (Wilson et al., 
2003), most all change points were identified as occurring within five to ten years of death. Even 
typical hold tests tapping into Verbal IQ, which appear to decline last in regard to dementia 
(Grober et al., 2008), declined within this five-year window, evidencing a global decline in 
cognitive functioning across domains preceding death. 
Variables Modifying the Onset and Rate of Cognitive Decline 
The second aim focused on determining factors that modify the location of a change point 
in relation to MCI, dementia, or death along with the rates of change both before and after the 
change point. The MCI studies involved limited focus on covariates, considering there were few 
of them, and they involved the analysis of only the OBAS cohort. They found some effects of 
gender on motor outcomes, where earlier change points for gait speed and finger tapping were 
observed for men than women. Similarly, few modifying variables were evaluated for dementia 
studies overall, but some showed a meaningful effect of the change point or rate of change. With 
more years of education, the change point was delayed, but once accelerated change began, it 
occurred at a more rapid rate for individuals with more education (Hall et al., 2007; Jacqmin‐
Gadda et al., 2006). Participants involved more frequently in cognitively engaging activities 
(e.g., reading, crossword puzzles, playing music) also experienced a delay in the onset of a faster 
rate of decline (Hall et al., 2009). In terms of dementia type, decline occurred earlier among 
participants with AD than VaD (Laukka et al., 2012). Dementia type was only evaluated as a 
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change point modifier in one study; while in all other studies, participants were either grouped as 
a single dementia cohort or the subgroup with AD diagnoses were separately evaluated.  
The number of covariates evaluated in the terminal decline studies far exceeded those 
evaluated among either the MCI or dementia cohorts. For some covariates there were discrepant 
findings. While one study found no effect of gender decline before the change point (Muniz-
Terrera et al., 2013), another found that women declined faster before the change point (Muniz 
Terrera et al., 2014); and while one study found women decline at a faster rate following the 
change point (Muniz-Terrera et al., 2013), another found that women declined at a slower rate 
following the change point (Muniz Terrera et al., 2014). Education as a covariate produced 
similarly discrepant findings, where two studies found that more education delayed the change 
point (Batterham et al., 2011; Muniz Terrera et al., 2014), but the rate of accelerated decline was 
either faster with more education (Muniz Terrera et al., 2014), faster with less education 
(Batterham et al., 2011; Muniz-Terrera et al., 2013), or education had no effect at all (Wilson et 
al., 2007). Personality was also explored as a covariate, where one study determined that higher 
levels of conscientiousness was not associated with the location of the change point, but did lead 
to a slower rate of terminal decline (Wilson et al., 2015). 
Aside from demographic characteristics, genetic risk and neuropathology were also 
explored. The presence of an APOE ε4 allele was related to an earlier change point and a more 
rapid rate of terminal decline (Wilson et al., 2007; Yu et al., 2013); however, AD neuropathology 
explained the relationship between APOE ε4 and components of the change point model, as the 
relationship between APOE ε4 and model components became non-significant with the inclusion 
of AD neuropathologic indices as covariates in the model (Yu et al., 2013). Multiple 
neuropathologic indices of AD were evaluated as covariates (e.g., tangles, neuritic plaques, 
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neocortical Lewy bodies, etc.), explaining a substantial amount of variance in the change point 
along with the pre-terminal and terminal rates of decline (Boyle et al., 2013; Wilson et al., 2015). 
Limitations 
The studies reviewed herein were variable in terms of their research designs, cognitive 
measurements, and analytic approaches, limiting the conclusions that can be drawn from the 
current systematic review. Among the many longitudinal cohort studies evaluated, the study 
durations, number of completed measurement waves, and intervals between measurement waves 
varied substantially. Studies ranged in duration from 10 years (Jacqmin‐ Gadda et al., 2006; 
Laukka et al., 2012) to 30 years (Thorvaldsson et al., 2008; Thorvaldsson et al., 2011). The 
number of completed measurement waves varied from 2 (for a study with up to five waves; 
MacDonald et al., 2011) to 8.6 (for a study with up to 18 waves; Boyle et al., 2013). Attrition is 
not uncommon for longitudinal research, especially among older adults who experience dementia 
or death during follow-up; however, for some cohorts, many participants completed just a small 
number of measurement waves on average. The inter-test intervals ranged from annual (which 
was the most common) to up to five years (Muniz-Terrera et al., 2013; Muniz Terrera et al., 
2014; van den Hout et al., 2011). Studies with long intervals between measurement waves may 
fail to detect the precise onset of change. If a participant undergoes a change point within months 
of their last measurement, but must wait years till their next assessment, the analysis would 
misestimate the temporal onset of accelerated decline, biasing the change point estimates 
calculated for these participants. Comparing change points for studies with such variable 
intervals may be a reason for the inconsistent findings across studies, where variability in change 
point estimation may be a consequence of discrepant research designs. 
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In addition to research designs, the cognitive measures used were also highly variable 
across studies, with very little overlap. Many tests were assumed to measure the same construct, 
but they all have unique psychometric characteristics, including different methods of scoring 
(e.g., total correct, time-to-completion), different reliability estimates, and different evidence for 
validity. The psychometric qualities of each outcome were not evaluated in the current review, 
but measurement may influence the variability in change points estimated across studies. For 
example, the MMSE has a well-known ceiling effect, where most all healthy participants obtain 
either the highest possible score, or close to the highest possible score. In the context of detecting 
a change point, older adults may begin accelerated decline years before this decline is detected 
by the MMSE, with the change points reported in published studies representing an end of the 
ceiling effect rather that the true onset of accelerated cognitive decline. 
Lastly, the analytical approaches taken by previous researchers also showed substantial 
inconsistency. There is no consensus on the best modeling or estimation approach when 
detecting change points, and models varied regarding whether they included random effects and 
whether they used frequentist or Bayesian estimation. Further, the variable inclusion or exclusion 
of covariates across studies blurs the inferences that can be drawn from the literature in 
aggregate. There was no common inclusion of covariates across studies, which is likely why 
some predictors varied in their significance across studies. Considering between-study 
differences in the significance of covariates, there is also a risk of selective reporting, where 
covariates that were found to be non-significant were not reported in published findings. This 
review did not involve a formal evaluation of this type of bias across studies, but such bias could 
have affected the representation of different covariates in the published literature on preclinical 
and terminal change points among older adults. 
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Future Directions 
To date, the change point research has evidenced the clear preclinical or terminal change 
points that occur years before diagnosis or death; and – based on the evaluation of covariates – it 
is also clear that demographic, genetic, and neuropathologic factors are associated with the onset 
and rate of decline. However, inference around these modifying variables is clouded by the 
inconsistent inclusion of covariates across studies. Considering the discrepancies across studies 
in terms of the estimation approach, cognitive measurements, statistical modeling, and the 
inclusion or exclusion of covariates, a coordinated analysis of multiple datasets may provide an 
improved method of drawing inference on change point studies across cohorts (Hofer & Piccinin, 
2009). It is clear based on the current findings that gender and education are both commonly 
measured and have some effect on components of change point models; and these demographic 
features should likely be included as covariates across future models to promote comparability. 
Baseline age is also a candidate for a common covariate in future analyses, as most all studies 
reported this demographic, but only one evaluated its significance (Muniz-Terrera et al., 2013). 
Through analytical coordination, the results of future change point models could be as 
comparable as possible, allowing for stronger inferences to be drawn about the time at which 
accelerated change begins and the variables that modify the onset and rates of change. 
The identification of modifying variables is likely the most useful research finding that 
can be drawn from change point research. Although meaningful at a population level, the 
average onset of preclinical decline is of little meaning at the individual patient level unless 
clinicians know both when to predict decline and how to delay or slow its acceleration. 
Demographic features, genetic data, and neuroimaging results would support prediction, but 
modifying the onset and rate of decline requires either behavioral change or intervention. Change 
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point analysis could be useful in future intervention research, where the experimental condition 
could serve as a covariate, determining the delay in decline attributable to treatment. However, 
change point analysis may be most useful when determining the interaction between patient 
characteristics (e.g., age, gender, APOE ε4 status, white matter hyperintensities) and the 
effectiveness of a given intervention. Such advances in “precision health” are particularly 
important in research on dementia, with its long prodromal period and current limitations of 
clinical detection of neurological impairment, and where signs and symptoms may emerge 
clearly only years after neuropathological change has accumulated in the brain. Improvement in 
change point estimation and individualized risk models will provide information to support a 
precision health approach to the design of effective interventions to delay the onset or slow the 
rate of decline caused by dementia and related disorders. 
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Table 1. MCI Change Point Studies: Participant Characteristics 
Cohort Study n* x̄ Age (SD) Age Range % Male Education (x̄ years)  % White % APOE ε4+ MCI Definition 
          
          
OBAS Buracchio et al. (2010)  95 83.5 (7.0) 65-98 39.0 14.7 – 27.7  ≥2 consecutive CDRs 
≥0.5; No functional 
impairment 
 
 Carlson et al. (2008)  37 84.8 (6.9) 66-97 35.1 13.8 – 24.3 Same as above 
 
 Howieson et al. (2008)  68 84.9 (5.0) 65-110 33.8 14.6 98.1
†
 – Same as above 
 
 Silbert et al. (2012)  134 84.8 (5.9) 65-102 38.8 14.2 – 20.9 Same as above 
 
Note. % APOE ε4+ = Percent positive for the Apolipoprotien E e4 allele; CDR = Clinical Dementia Rating Scale; Educ. = Education; MCI = Mild Cognitive Impairment; OBAS = 
Oregon Brain Aging Study 
 
*n values correspond to the sample size of participants that ultimately received an MCI diagnosis and were included in analysis. 
†
Value derived from the full sample, rather than just the sub-sample experiencing MCI. 
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Table 2. Dementia Change Point Studies: Participant Characteristics 
Cohort Study n* x̄ Age (SD) Age 
Range 
% 
Male 
Educ. (x̄ yrs. or specified)  % White % APOE 
ε4+ 
MCI/Dementia Definition 
          
ADC NDI Ji et al. (2003)  92 76.9 (9.4) – – 14.1 – – No definition provided, but sample described as 
having a definitive AD diagnosis 
 
ADRC Johnson et al. (2009)  134 80.4 (8.9) 60-101 34.0 14.1 – 27.0 CDR = 0.5  Uncertain Dementia; 
CDR ≥0.5  AD; based on semi-structured 
interviews with participants/collateral sources, 
health history, medication/depression 
inventories, aphasia assessment, and neurologic 
examination 
 
BLSA Grober et al. (2008)  92 79.8 (6.9) – 48.0 16.5 – – Dementia (APA, 1980); 
Probable/Possible AD (McKhann et al., 1984) 
 
BAS
†
 Hall et al. (2000)  125 
(71 w/ 
AD) 
80.5 (3.3) 75-85 35.5 Mode of 7th-9th Grade 90 – Dementia (APA, 1980); Probable AD 
(McKhann et al., 1984); MID based on clinical 
features and modified Hachinski ischemic score 
(Rosen et al., 1980) 
 
 Hall et al. (2001)  69 Same as above >8 on Blessed Information Memory 
Concentration Test 
 
 Hall et al. (2003)  69 Same as above 
 
 
 Hall et al. (2007)  117 M = 81 74-92 32.0 82.1% <12 years 90 – Dementia (American Psychiatric Association. 
Work Group to Revise & American Psychiatric, 
1987) 
 
 Hall et al. (2009)  101 79.5 73-87 38.0 – 91 – Dementia (American Psychiatric Association. 
Work Group to Revise & American Psychiatric, 
1987) 
 
H70 Thorvaldsson et al. (2011)  127 70 70-70 34.0 33% w/ >6 years – – Dementia (American Psychiatric Association. 
Work Group to Revise & American Psychiatric, 
1987) 
 
KP Laukka et al. (2012)  286 w/ 
AD 
 
82.5 (4.7) – 14.3 56.6% <8 years – – Dementia (A. P. Association, 1980) 
AD (McKhann et al., 2011)  
 
  63 w/ 
VaD 
 
82.1 (4.9) – 23.8 52.4% <8 years – – Dementia (A. P. Association, 1980) 
VaD (Román et al., 1993) 
 
 Thorvaldsson et al. (2011)  279 82 ≥75 18.0 43% w/ >7 years – – Dementia (American Psychiatric Association. 
Work Group to Revise & American Psychiatric, 
1987) 
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PP Jacqmin-Gadda et al. (2006)  314 – ≥65 – 43.3% w/out primary 
school 
 
– – Dementia (American Psychiatric Association. 
Work Group to Revise & American Psychiatric, 
1987) 
ROS/MAP Li et al. (2015)  429 81.5 (6.6) 64-102 26.8 79.3% ≤12 years – 29.6 AD (McKhann et al., 2011) 
 
 
Note. % APOE ε4+ = Percent positive for the Apolipoprotein E e4 allele; AD = Alzheimer’s disease; ADC NDI = Alzheimer’s Disease Centers Neuropsychological Database 
Initiative; ADRC = Washington University School of Medicine Alzheimer’s Disease Research Center; APA = American Psychiatric Association; BAS = Bronx Aging Study; 
BLSA = Baltimore Longitudinal Study of Aging; CDR = Clinical Dementia Rating Scale; Educ. = Education; H70 = Gerontological and Geriatric Population Study; KP = 
Kungsholmen Project; PP = Paquid Project; MAP = Memory and Aging Project; MID = Multi-infarct Dementia; ROS = Religious Orders Study; VaD = Vascular Dementia.  
 
*n values correspond to the sample size of participants that ultimately received a dementia diagnosis or died over the course of the study and were included in analysis. 
†For Hall et al. (2001, 2001), demographic characteristics for the BAS sample and the diagnostic criteria for dementia and Alzheimer’s disease were pulled from another article 
(Katzman et al., 1989).  
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Table 3. Terminal Decline Change Point Studies: Sample Size Included in Analysis and Baseline Participant Characteristics 
Cohort Study n* x̄ Age (SD) Age Range % Male Educ. (x̄ years or 
specified)  
% White % APOE ε4+ 
         
BAS Sliwinski et al. (2006)  
 
445 79.3 (3.1) 75-85 – – – – 
CC75C  Muniz-Terrera et al. (2013)  
 
1,896 81 ≥75 35.0 – – – 
 Muniz-Terrera et al. (2014)  2,078
†
 81 ≥75 35.0 Left school at x̄ age 
14.8 years 
  
– – 
 van den Hout et al. (2011)  
 
156 81.6 ≥75 – – – – 
CLS Batterham et al. (2011)  
 
687 77.3 (5.1) ≥70 50.9
‡
 11.4 – – 
H70 Thorvaldsson et al. (2008)  
 
288 70 All 70 43.8 – – – 
MoVIES Dodge et al. (2011)  613 74.3 (6.0) 64-95 49.8 54.3% w/ high 
school or more 
 
– – 
MAP Wilson et al. (2007)  
 
115 83.7 (5.1) – 41.7 14.7 91.6
§
 29.5 
OCTO-Twin van den Hout et al. (2013)  
 
656 – ≥80 – – – – 
ROS Wilson et al. (2003)  
 
122 80.5 (6.3) – 48.4 18.3 – – 
ROS/MAP Boyle et al. (2013)  
 
573 – – 36.05 16.55 95
¶
 – 
 Wilson et al. (2015)  
 
309 – ≥50 35.3 18.2 – – 
 Yu et al. (2013)  
 
581 88.9 (6.5) 71-108 34.4 – – 23.8 
VLS MacDonald et al. (2011)  265 72.7 (6.4) 55-85
#
 – – – – 
 
Note. % APOE ε4 = Percent positive for the Apolipoprotein E e4 allele; BAS = Bronx Aging Study; CC75C = Cambridge City over 75 Cohort Study; CLS = Canberra 
Longitudinal Study; Educ. = Education; H70 = Gerontological and Geriatric Population Study; MoVIES = Monongahela Valley Independent Elders Survey; OCTO-Twin = 
Origins of Variance in the Old-old Study; MAP = Memory and Aging Project; ROS = Religious Orders Study; VLS = Victoria Longitudinal Study. 
 
*n values correspond to the sample size of participants that ultimately died over the course of the study and were included in analysis. 
†Muniz-Terrera et al. (2014) specified that only five participants from the baseline cohort were alive at the time of analysis. It is not clear from the article whether the n value 
reported was the sample size included in analysis and whether this value is inclusive of participants that did not pass away during follow-up. 
‡Percent Male for Batterham et al. (2011) derived from the full sample, not just participants dying during follow-up. 
§Percent White for Wilson et al. (2007) derived from the full sample, not just participants dying during follow-up. 
¶Values taken from full sample reported in manuscript, although only subsample of participants used in change point analysis. 
#For MacDonald et al. (2011), the age range was provided for all participants in the VLS, not just those dying at follow-up. 
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Table 4. MCI Change Point Studies: Study Design Characteristics, Outcomes and Change Points 
Cohort Authors (Year) Duration 
(Years) 
Max # 
MWs 
# MWs: 
x̄ (SD) 
Years 
Follow-up 
x̄ (SD) 
Interval 
Duratio
n 
(Years) 
Bayesian/ 
Frequentist; 
Random/ 
Fixed CP 
Covariates Outcome Construct CP (95% CI) in Years to Dx 
            
OBAS Buracchio et al. (2010)  20 20 – 10.5 (4.0) 1 Frequentist; 
Fixed CP 
Age, education, 
sex, APOE ε4 
status, baseline 
speed, stroke, 
and depression 
 
Gait Speed Motor Men/Women: -12.1 (Unknown to -8.1) 
Men: -14.2 (Unknown to -8.7) 
Women: -6.0 (-9.5 to -4.6) 
         Finger Tapping: 
Dominant Hand 
Motor Men/Women: 3.75 (1.66 to 4.66) 
Men: -5.91 (-10 to 6.5) 
Women: 3 (0.16 to 4.91) 
 
         Finger Tapping: 
Non-Dominant 
Hand 
Motor Men/Women: 2.66 (-0.25 to 4.33) 
Men: 6.16 (-7.66 to 6.83) 
Women: 0.41 (-1.75 to 2.88) 
 
 Carlson et al. (2008)  15 12 6.0 (3.3) 6.3 (3.6) 1 Frequentist; 
Fixed CP 
 
– Ventricular 
Volume 
Neurological -2.3 (-5.6 to -0.3) 
 
 Howieson et al. (2008)  – – – 8.0 (2.8) 1 Frequentist; 
Fixed CP 
– LM I, Story A Verbal Memory -2.9 (-4.0 to -1.5) 
         LM II, Story A Verbal Memory -3.1 (-4.5 to -2.1) 
         Animal Fluency Fluency -3.9 (-5.1 to -3.1) 
         Block Design Visuospatial 
Ability 
 
-3.9 (-5.4 to -2.9) 
 Silbert et al. (2012)  19.6 15 M = 4.0 10.4 (4.1) 1 Frequentist; 
Fixed CP 
Age, gender, 
APOE ε4 status, 
diabetes, HTN, 
smoking, 
stroke/TIA, and 
baseline 
intracranial and 
hippocampal 
volume 
WMH Neurological -10.58 (Unknown to -5.16) 
         Ventricular CSF 
Volume 
Neurological -3.66 (-5.58 to -0.75) 
 
Note. APOE ε4 = Apolipoprotein E e4 allele; CI = Confidence or Credible Interval; CLS = Canberra Longitudinal Study; CP = Change Point; CSF = Cerebrospinal Fluid; HTN = Hypertension; LM = 
Logical Memory; MWs = Measurement Waves; OBAS = Oregon Brain Aging Study; WMH = White Matter Hyperintensities. 
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Table 5. Dementia Change Point Studies: Study Design Characteristics, Outcomes and Change Points 
Cohort Authors (Year) Duration 
(Years) 
Max 
# 
MWs 
# MWs: 
x̄ (SD) 
Years 
Follow-up 
x̄ (SD) 
Interval 
Duration 
(Years) 
Bayesian/ 
Frequentist; 
Random/ 
Fixed CP 
Covariates Outcome Construct CP (95% CI) in Years to Dx 
            
ADC NDI Ji et al. (2003)  12 – – – – Frequentist; 
Fixed CP 
 
– MMSE Global AD-Only: -5 
 
WUSM 
ADRC 
Johnson et al. (2009)  25.7 – 7.1
*
 
5.9 (5.3) 1 Frequentist; 
Fixed CP 
Age, 
education 
Global Factor Global AD-Only: -2 
         Verbal Memory 
Factor 
Verbal 
Memory 
AD-Only: -1 
         WMS Associate 
Learning 
Verbal 
Memory 
AD-Only: -4 
         WMS Logical 
Memory 
Verbal 
Memory 
AD-Only: -2 
         Visuospatial Factor Visuospatial AD-Only: -3 
         Working Memory 
Factor 
Executive 
Function 
 
AD-Only: -1 
BLSA Grober et al. (2008)  15 – – 4.6 2.4 Frequentist; 
Fixed CP 
– FCSRT Verbal 
Memory 
Two Change Points Reported: 
AD-Only: -7.1 (Unknown to -5) 
AD-Only: -2.6 (CI Not Reported) 
         Category Fluency Fluency AD-Only: -3 (-5.0 to -1.7) 
         Letter Fluency Fluency AD-Only:  -2.5 (-4.9 to -1.5) 
         Trail Making Test 
Part B 
Executive 
Function 
AD-Only: -2.9 (-8.3 to -1.1) 
         AMNART Verbal IQ AD-Only: -0.4 (-1.1 to 0.1) 
 
BAS Hall et al. (2000)  18 10 – – 1 Frequentist; 
Fixed CP 
 
– BSRT Verbal 
Memory 
Dementia: -5.1 (-6.1 to -4.2) 
AD-Only: -4.3 (-5.5 to -2.6) 
 
Hall et al. (2001)
†   
19 – – – 1-1.5 Bayesian & 
Frequentist; 
Random & 
Fixed CPs 
 
– BSRT Verbal 
Memory 
Dementia: -7.3 (-9.0 to -3.1) 
 
         WAIS-III PIQ Visuospatial 
Ability 
Dementia: -3.0 (-4.1 to -1.6) 
 Hall et al. (2003)  20 – – – 1 Bayesian & 
Frequentist; 
Random & 
Fixed CPs 
 
– BSRT Verbal 
Memory 
 
Dementia: -7.96 (-9.9 to -1.2) 
 Hall et al. (2007)  27 – 2.7; 
3.6; 
4.23 
 
– ~1.5
‡
 
Frequentist; 
Fixed CP 
Education BSRT Verbal 
Memory 
Dementia: -5.5 (-7.0 to -4.2) 
 Hall et al. (2009)  28 – 3.5
§
 5.0
§
 
1-1.5 Frequentist; 
Fixed CP 
Cognitive 
activity, 
education 
BSRT Verbal 
Memory 
 
Dementia: -5.5 (-7.1 to -4.0) 
H70 Thorvaldsson et al. (2011)  30 12 – – ~2.5 Frequentist; 
Fixed CP 
 Synonym Test Verbal IQ Dementia: -5.9 (-7.1 to -4.6) 
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         Block Design Visuospatial 
Ability 
Dementia: -8.6 (-11.6 to -5.6) 
         Figure Identification Processing 
Speed 
 
Dementia: -10.9 (-14.4 to -7.5) 
KP Laukka et al. (2012)  10 4 2.8 (1.0) – 3 Frequentist; 
Fixed CP 
– Word Recall Verbal 
Memory 
AD-Only: -8.1 (Unknown to -7.7) 
VaD-Only: -6.5 (Unknown to -3.1) 
         Word Recognition Verbal 
Memory 
AD-Only: -7.1 (-9.2 to -6.1) 
VaD-Only: -4.8 (-6.8 to -3.3) 
         Block Design Visuospatial 
Ability 
AD-Only: -9.6 (Unknown to -6.8) 
VaD-Only: -5.3 (Unknown to -3.7) 
         Category Fluency Fluency AD-Only: -6.8 (-9.0 to -5.2) 
VaD-Only: -4.4 (-5.7 to -3.1) 
         Clock Reading Visuospatial 
Ability 
AD-Only: -4.5 (-5.1 to -3.4) 
VaD-Only: -4.8 (-7.2 to -3.4) 
 
 Thorvaldsson et al. (2011)  13 4 – – 3 Frequentist; 
Fixed CP 
Baseline 
Age 
Word Recall Verbal 
Memory 
Dementia: -8.6 (Unknown to -6.2) 
         Block Design Visuospatial 
Ability 
Dementia: -8.3 (Unknown to -5.4) 
         Category Fluency Fluency Dementia: -4.6 (-6.5 to -3.5) 
         Clock Reading Visuospatial 
Ability 
 
Dementia: -4.1 (-5.9 to -2.8) 
PP 
Jacqmin-Gadda et al. (2006)
¶
  
10 6 – – ~2 Frequentist; 
Random CP 
Education BVRT Visual 
Memory 
 
– 
ROS/MAP Li et al. (2015)  – 12 7.1 (2.8) – 1 Quantile 
Regression 
w/ CP 
Gender, 
education, 
APOE ε4 
status 
Episodic Memory 
Composite
#
 
Verbal 
Memory 
AD-Only: -4.6 (-5.0 to -4.1) ** 
 
Note. AD = Alzheimer’s disease; APOE ε4 = Apolipoprotein E e4 allele; ADC NDI = Alzheimer’s Disease Centers Neuropsychological Database Initiative; AMNART = American Version of the 
Nelson Adult Reading Test; BAS = Bronx Aging Study; BLSA = Baltimore Longitudinal Study of Aging; BSRT = Buschke Selective Reminding Test; BVRT = Benton Visual Retention Test; CI = 
Confidence or Credible Interval; CP = Change Point; FCSRT = Free and Cued Selective Reminding Test; H70 = Gerontological and Geriatric Population Study; KP = Kungsholmen Project; MMSE = 
Mini Mental Status Examination; MWs = Measurement Waves; PP = Paquid Project; MAP = Memory and Aging Project; ROS = Religious Orders Study; VaD = Vascular Dementia; WAIS-III PIQ = 
Wechsler Adult Intelligence Scale, Third Edition, Performance IQ; WMS = Wechsler Memory Scale; WUSM ADRC = Washington University School of Medicine Alzheimer’s Disease Research 
Center. 
 
* 
For Johnson et al. (2009), the average number of observations was calculated by dividing the total assessments for participants progressing to AD (i.e., 957) by the number of participants progressing 
to AD (n = 134) 
†
For Hall et al. (2001), the change points provided are for full models, but the authors also reported two reduced models with similar results. 
‡
For Hall et al. (2007), the mean number of visits before dementia diagnosis was broken down by three groups, displayed in the following order within the table: Education ≤ 7 years; 8-11 years; ≥ 12 
years (No significant difference was observed between groups for this variable). The mean testing interval durations were also divided by education level for this study, but they were all approximately 
1.5 years. 
§
For Hall et al. (2009), the average number of years follow-up was calculated by dividing the total number of person-years reported (i.e., 505) by the number of participants in the analysis (i.e., 101). 
The average number of visits was calculated by dividing the total number of clinic visits (i.e., 351) by the number of participants (i.e., 101). 
¶
Jacqmin-Gadda et al. (2006) included a random change point and did not report a mean or modal change point in relation to dementia diagnosis for the sample evaluated. 
#
Tests included in composite provided in Wilson et al. (2002). 
**Li et al. (2015) reported a quantile regression with change points reported for the 20th, 50th, and 80th percentile. The change point provided here is the one for the 50th percentile. 
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Table 6. Terminal Decline Change Point Studies: Study Design Characteristics, Outcomes and Change Points 
Cohort Authors (Year) Duration 
(Years) 
Max # 
MWs 
# MWs: 
x̄ (SD) 
Years 
Follow-up 
x̄ (SD) 
Interval 
Duration 
(Years) 
Bayesian/ 
Frequentist; 
Random/ 
Fixed CP 
Covariates Outcome Construct CP (95% CI) in Years to Death 
            
BAS Sliwinski et al. (2006)  – – – 5.7 – Frequentist; 
Fixed CP 
Dementia 
diagnosis 
BSRT Verbal 
Memory 
 
-8.4 (-9.8 to -7.1) 
CC75C  Muniz-Terrera et al. (2013)  17 7 – – – Bayesian; 
Both 
Education, 
gender, age at 
death, baseline 
physical and 
cognitive 
impairment 
 
MMSE Global -7.7 (-8.1 to -7.2)
*
 
 Muniz-Terrera et al. (2014)  21 7 – – 2-5 Bayesian; 
Random CP 
Education, 
gender, age at 
death, baseline 
physical and 
cognitive 
impairment 
 
MMSE Global -6.2 (-6.6 to -5.7) 
 van den Hout et al. (2011)  21 7 – – 2-5 Bayesian; 
Random CP 
 
– MMSE Global -6.1 
CLS Batterham et al. (2011)  12 4 2.0
†
 – – Frequentist; 
Fixed CP 
Education, 
gender, heart 
attack/hyper-
tension, grip 
strength, smoking, 
functional ability, 
disease count, and 
depression 
MMSE Global -7.1 (-9.3 to -6.2) 
         Symbol-Letters 
Modalities Test 
Processing 
Speed 
-8.5 (-11.2 to -6.0) 
         Brief Episodic 
Memory Tasks
‡
 
 
Memory -6.6 (-7.1 to -5.3) 
H70 Thorvaldsson et al. (2008)  30 12 – – ~2.5 Frequentist; 
Fixed CP 
– Synonym Test Verbal IQ -6.6 (-11.7 to -4.3) 
         Block Design Visuospatial 
Ability 
-7.8 (-10.6 to -6.3) 
         Figure Identification Processing 
Speed 
-14.8 (-16.6 to -10.8) 
MoVIES Dodge et al. (2011)
§  14 9 – 6.8 (4.0) 1.5 Frequentist; 
Fixed CP 
Education, sex, 
sampling group, 
and practice 
effects 
Learning Composite Learning -7.4 (-8.9 to -5.4) 
         Memory Composite Memory -7.6 (-9.9 to -5.3) 
         Psychomotor Speed 
Composite 
Processing 
Speed 
-9.4 (-13.1 to -5.8) 
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         Executive Function 
Composite 
Executive 
Function 
-9.8 (Unknown to -8.1) 
         Language Composite Language -9.8 (Unknown to -8.3) 
MAP Wilson et al. (2007)  9 9 4.0 – 1 Frequentist; 
Fixed CP 
Education, 
age, sex 
 
Global Composite Global -3.5
¶
 
gOCTO-
Twin 
van den Hout et al. (2011)  10 5 3.1
#
 – 2 Frequentist; 
Random CP 
 
– MMSE Global -5.8 
ROS Wilson et al. (2003)
**
  8 9 5.6 – 1 Frequentist; 
Fixed CP 
Age, sex, 
education, 
medical 
conditions, 
disability 
Global Composite Global -3.6 
         Perceptual Speed Processing 
Speed 
-2.8 
         Episodic Memory Verbal 
Memory 
-3.4 
         Semantic Memory Language -3.3 
         Working Memory Executive 
Function 
-3.8 
         Visuospatial Ability Visuospatial 
Ability 
 
-6.0 
ROS/MAP Boyle et al. (2013)  18 18 8.6 (3.0) – 1 Bayesian; 
Random CP 
Global AD 
pathology, 
amyloid, tangles, 
gross and micro 
infarcts, Lewy 
bodies 
 
Global Cognition 
Summary Measure 
Global -3.0 (-3.2 to -2.8) 
 Wilson et al. (2015)  – – – 10.7 (4.0) 1 Bayesian; 
Random CP 
Age at death, sex, 
education, 
conscientiousness, 
neuroticism, 
depressive 
symptoms, 
tangles, gross and 
micro infarcts, 
Lewy bodies, 
hippocampal 
sclerosis 
 
Global Cognition 
Summary Measure 
Global -3.2 (-3.6 to -2.8) 
 Yu et al. (2013)  17 – – 8.0 1 Bayesian; 
Random CP 
Age, sex, 
education, APOE 
ε4 status, global 
AD pathology, 
amyloid, tangles, 
gross and micro 
infarcts, Lewy 
bodies 
 
Global Cognition 
Summary Measure 
Global APOE ε4-: -3.2 (-3.5 to -2.9) 
APOE ε4+: -4.0 (-4.7 to -3.2) †† 
VLS MacDonald et al. (2011)  12 5 2.0
‡‡
 8.1 3 Frequentist; 
Fixed CP 
Age at death  Semantic 
Verification 
Processing 
Speed 
-9.5 
         Sentence 
Construction 
Executive 
Function 
-3.5 
         Word Recall Verbal 
Memory 
-6.8 
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         Fact Recall Verbal IQ -8.2 
         Vocabulary Verbal IQ -6.4 
 
Note. AD = Alzheimer’s disease; ADC NDI = Alzheimer’s Disease Centers Neuropsychological Database Initiative; AMNART = American Version of the Nelson Adult Reading Test; APOE ε4 = 
Apolipoprotein E e4 allele; BAS = Bronx Aging Study; BLSA = Baltimore Longitudinal Study of Aging; BSRT = Buschke Selective Reminding Test; BVRT = Benton Visual Retention Test; CC75C = 
Cambridge City over 75 Cohort Study; CDR = Clinical Dementia Rating Scale; CI = Confidence or Credible Interval; CLS = Canberra Longitudinal Study; CSF = Cerebrospinal Fluid; FCSRT = Free 
and Cued Selective Reminding Test; H70 = Gerontological and Geriatric Population Study; KP = Kungsholmen Project; LM = Logical Memory; MMSE = Mini Mental Status Examination; MoVIES = 
Monongahela Valley Independent Elders Survey; MWs = Measurement Waves; OBAS = Oregon Brain Aging Study; OCTO-Twin = Origins of Variance in the Old-old Study; PP = Paquid Project; 
MAP = Memory and Aging Project; ROS = Religious Orders Study; VaD = Vascular Dementia; VLS = Victoria Longitudinal Study; WAIS-III PIQ = Wechsler Adult Intelligence Scale, Third Edition, 
Performance IQ; WMH = White Matter Hyperintensities; WMS = Wechsler Memory Scale; WUSM ADRC = Washington University School of Medicine Alzheimer’s Disease Research Center. 
 
*Muniz-Terrera et al. (2013) reported a change point of -5.66 (-6.08 to -5.24), but subtracted 2 years from this value because time zero was coded as two years to death. 
†For Batterham et al. (2011), the average number of visits was calculated by dividing the total number of observations (i.e., 1406) by the number of participants (i.e., 687). 
‡Brief episodic memory tasks included both visual and verbal recall (e.g., word, face, name, and address recall; and figure reproduction) 
§ Dodge et al. (2011) reported change points with and without controlling for practice effects. Those reported here are the change points controlling for practice effects. 
5Wilson et al. (2007) did test change points for other domains, but either did not find a difference between the global change point and the construct-specific change points or found the identification of a 
change point ambiguous based on profile likelihood values. 
¶For van den Hout et al. (2012), the mean number of observations was calculated by dividing the number of records (i.e., 2024) by the number of participants (i.e., 656). 
#For Wilson et al. (2007), the longitudinal design data were taken for the full sample, not just those dying at follow-up. 
††For Yu et al. (2013), the change point for APOE ε4 carriers was calculated by adding the additional burden for carriers reported by the authors to the change point and 95% CI reported for non-
carriers. 
‡‡For MacDonald et al. (2011), the mean number of observations was calculated by summing the number of measurement waves completed by participants and dividing that sum by the total number of 
participants. 
 
Note. AD = Alzheimer’s disease; ADC NDI = Alzheimer’s Disease Centers Neuropsychological Database Initiative; AMNART = American Version of the Nelson Adult Reading Test; APOE ε4 = 
Apolipoprotein E e4 allele; BAS = Bronx Aging Study; BLSA = Baltimore Longitudinal Study of Aging; BSRT = Buschke Selective Reminding Test; BVRT = Benton Visual Retention Test; CC75C = 
Cambridge City over 75 Cohort Study; CDR = Clinical Dementia Rating Scale; CI = Confidence or Credible Interval; CLS = Canberra Longitudinal Study; CSF = Cerebrospinal Fluid; FCSRT = Free 
and Cued Selective Reminding Test; H70 = Gerontological and Geriatric Population Study; KP = Kungsholmen Project; LM = Logical Memory; MMSE = Mini Mental Status Examination; MoVIES = 
Monongahela Valley Independent Elders Survey; MWs = Measurement Waves; OBAS = Oregon Brain Aging Study; OCTO-Twin = Origins of Variance in the Old-old Study; PP = Paquid Project; 
MAP = Memory and Aging Project; ROS = Religious Orders Study; VaD = Vascular Dementia; VLS = Victoria Longitudinal Study; WAIS-III PIQ = Wechsler Adult Intelligence Scale, Third Edition, 
Performance IQ; WMH = White Matter Hyperintensities; WMS = Wechsler Memory Scale; WUSM ADRC = Washington University School of Medicine Alzheimer’s Disease Research Center.
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 Terminal Decline (n=14) 
Number of records after duplicates removed 
(n=74) 
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Figure 2. Change Point Estimates with 95% Confidence Intervals for MCI Studies by Construct 
 
Note. CSF = Cerebrospinal Fluid; LM = Logical Memory; MCI = Mild Cognitive Impairment; WMH = White Matter 
Hyperintensities. Lower end confidence intervals for Gait Speed and WMH were unknown. All change points for motor 
outcomes come from the full sample (Men and Women) (Buracchio et al., 2010). 
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Figure 3. Change Point Estimates with 95% Confidence/Credible Intervals for Alzheimer’s 
Disease Studies by Construct 
 
Note. ADC NDI = Alzheimer’s Disease Centers Neuropsychological Database Initiative; ADRC = Washington University School of Medicine 
Alzheimer’s Disease Research Center; AL = Associate Learning; AMNART = American Version of the Nelson Adult Reading Test; BAS = 
Bronx Aging Study; BLSA = Baltimore Longitudinal Study of Aging; BSRT = Buschke Selective Reminding Test; EM = Episodic Memory; 
FCSRT = Free and Cued Selective Reminding Test; H70 = Gerontological and Geriatric Population Study; KP = Kungsholmen Project; LM = 
Logical Memory; MAP = Memory and Aging Project; MMSE = Mini Mental Status Examination; ROS = Religious Orders Study; TMT = Trail 
Making Test; WMS = Wechsler Memory Scale.  For the Bronx Aging Study, the only change point listed above is for the AD-only sample (Hall 
et al., 2000). One study (Johnson et al., 2009) reported a change point for a Verbal Memory factor, and separate change points for the tests that 
composed this Verbal Memory factor. The change points included in the figure above came from the individual tests and not the factor. Another 
study (Grober et al., 2008) provided two change points for the Free and Cued Selective Reminding Test. Only the first, earlier change point is 
displayed on the figure.  
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Figure 4. Change Point Estimates with 95% Confidence/Credible Intervals for Terminal Decline 
Studies by Construct 
 
Note. BAS = Bronx Aging Study; BSRT = Buschke Selective Reminding Test; CC75C = Cambridge City over 75 Cohort Study; CLS = Canberra 
Longitudinal Study; H70 = Gerontological and Geriatric Population Study; MMSE = Mini Mental Status Examination; MoVIES = Monongahela 
Valley Independent Elders Survey; OCTO-Twin = Origins of Variance in the Old-old Study; MAP = Memory and Aging Project; ROS = 
Religious Orders Study; VLS = Victoria Longitudinal Study. Three studies (Muniz-Terrera et al., 2013; Muniz Terrera et al., 2014; van den Hout 
et al., 2013) all reported change points for the MMSE using CC75C data, but only the change point for one study (Muniz Terrera et al., 2014) is 
displayed above. Five studies (Boyle et al., 2013;Wilson et al., 2003; Wilson et al., 2007;Wilson et al., 2015; Yu et al., 2013) provided change 
points for a Global Cognition Summary Measure using data from the ROS and/or MAP, but only the change point from one study  (Wilson et al., 
2015) is displayed above. 
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